UncategorizedMytos inks multiple cell therapy manufacturing partnerships – Longevity.Technology Empower Meds / September 3, 2025
UncategorizedNanoscope strengthens global regulatory pathways for MCO-010 – Longevity.Technology Empower Meds / September 3, 2025
UncategorizedFirst patient dosed in Citryll’s Phase IIa trial of CIT-013 in RA – Longevity.Technology Empower Meds / September 3, 2025
UncategorizedArrowhead inks $2b neurodegeneration deal with Novartis Empower Meds / September 2, 2025
UncategorizedVutrisiran shows long-term benefit in ATTR-CM Phase 3 study – Longevity.Technology Empower Meds / September 2, 2025
UncategorizedWegovy cuts heart attack, stroke and death risk in CVD patients Empower Meds / September 2, 2025
UncategorizedTelomir Pharmaceuticals sees new in vitro evidence supporting Telomir-1 epigenetic potential – Longevity.Technology Empower Meds / September 1, 2025
UncategorizedBanner year for Mesoblast with FDA approval and launch of Ryoncil – Longevity.Technology Empower Meds / September 1, 2025
UncategorizedAlnylam to advance zilebesiran into global phase 3 hypertension study – Longevity.Technology Empower Meds / September 1, 2025
